Kronox Lab Sciences Limited (KRONOX) Fair Value & Analysis
Basic Materials · IN · Market cap ₹6.0B
Fair value as of: Jul 3, 2026
From 25 valuation models · updated yesterday
Share price +18.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹98.59 – ₹204.98 · fair‑value band ₹63.45 – ₹150.40 · the ₹160.52 price screens above the ₹93.08 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Kronox Lab Sciences Limited (KRONOX) currently trades at ₹160.52, while our model-based Fair Value estimate is ₹93.08 — implying the stock looks roughly 42.0% overvalued today. We read business quality at 59/100 (solid quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Kronox Lab Sciences Limited generated revenue of ₹1.0B at a net margin of 27.3%. It earns a return on equity of 26.8%. The balance sheet holds a net cash position of ₹11.4M. The stock trades on a trailing P/E of 21.5. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Kronox Lab Sciences Limited manufactures and sells fine chemicals, inorganic chemicals, phosphates, and metallic chemicals in India and internationally. The company provides bulk reagents comprising ACS reagents, as well as LR, AR, and GR reagents; bulk ingredients that includes oral care, pharmacopoeia, food and nutraceutical, personal care and cosmetics, and veterinary pharma and animal health; and specialty chemicals, such as tartrates, citrates, hypophosphites, phosphates, hydroxides, EDTA and derivatives, ultra high purity chemicals, custom specification, and specialty anhydrous, as well as heat treatment, quenching, eutectic salt. Kronox Lab Sciences Limited was incorporated in 2008 and is based in Vadodara, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Kronox Lab Sciences Limited reported revenue of ₹1.0B in FY2026 versus ₹822M in FY2022, a compound +5.3%/yr. Reported net income was ₹277M in FY2026, compounding +19.4%/yr from FY2022.
Is KRONOX fairly valued? → Check now
Similar stocks
6 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $516.71 | $221.55 | -57% |
| L'Air Liquide S.A AIQUY | $37.81 | $15.56 | -59% |
| Air Products and Chemicals, Inc A1PD34 | R$360.05 | R$174.71 | -51% |
| Intercontinental Exchange, Inc I1CE34 | R$359.64 | R$307.76 | -14% |
| Wanhua Chemical Group 600309 | ¥67.90 | ¥46.52 | -31% |
| Asian Paints Limited ASIANPAINT | ₹2,674 | ₹739.38 | -72% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Kronox Lab Sciences Limited (KRONOX) undervalued?
What is the fair value of KRONOX?
What is the quality score of KRONOX?
What is the revenue of Kronox Lab Sciences Limited (KRONOX)?
What is the net profit margin of KRONOX?
Does Kronox Lab Sciences Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.